Scientific Integrity Tooling
We are funding science as if peer review can keep up, but industrial-scale fraud is outpacing traditional quality control.
The Stakes
Science is civilization’s error-correcting engine. If the engine gets polluted, everything slows: drug development, engineering, public trust, and AI alignment with reality. This is not “academic drama.” It is the integrity of the operating system for progress.
Headline evidence
- •A 2025 PNAS analysis argues entities enabling scientific fraud at scale are large, resilient, and growing rapidly. [1]
- •A landmark reproducibility analysis estimated irreproducible preclinical research may exceed 50%, costing about $28B per year in the U.S. alone (estimate based on past studies). [2]
- •Nature reports biomedical paper retractions have quadrupled over 20 years, driven largely by misconduct, indicating a scaling integrity crisis. [3]
Neglectedness
Why it stays neglected
Publishing incentives reward quantity. Fraud detection is costly and adversarial. Publishers fear reputational damage. Institutions often avoid aggressive enforcement. The victims are diffuse: future researchers, funders, and patients.
Tractability
Good. We can build integrity checks: image forensics, statistical anomaly detection, provenance verification, and reviewer identity validation. AI is both an accelerant for fraud and a defense tool. The hard part is deploying these tools at scale with low false positives and integrating with publisher workflows.
Startup surfaces
- Manuscript integrity scanners:images, statistics, citations, and text pattern analysis
- •Provenance and raw-data submission pipelines with standardized metadata and auditability
- •Reviewer identity and peer review process hardening (anti-broker, anti-fake reviewer)
- •“Clean corpus” curation services for labs, funders, and AI training datasets
- Incentive tooling for reproducibility:preregistration workflows and replication marketplaces
Source Stack (4)
- [1] Richardson RAK et al. The entities enabling scientific fraud at scale are large, resilient, and growing rapidly. (2025). (pnas.org )
- [2] Freedman LP et al. The economics of reproducibility in preclinical research. (2015). (journals.plos.org )
- [3] Else H. Biomedical paper retractions have quadrupled in 20 years. (Nature, 2024). (nature.com )
- [4] Parker L. Paper mill challenges: past, present, and future. (2024). (sciencedirect.com )
Builder Proof-of-Work
Community submitted artifacts, notes, and implementations for this idea.